Immunotherapy has revolutionised cancer treatment by stimulating the patient’s own immune system to attack cancer cells, yielding remarkably quick and complete remission in some cases.
But such drugs work for less than a quarter of patients because tumours are notoriously adept at evading immune assault.
A new study in mice by researchers at Washington University School of Medicine in St. Louis, USA, has shown that the effects of a standard immunotherapy drug can be enhanced by blocking the protein TREM2, resulting in complete elimination of tumours.
The findings, which are published in the journal Cell, point to a potential new way to unlock the power of immunotherapy for more cancer patients.
“Essentially, we have found a new tool to enhance tumour immunotherapy,” said senior author Marco Colonna, MD, the Robert Rock Belliveau, MD, Professor of Pathology.
“An antibody against TREM2 alone reduces the growth of certain tumours, and when we combine it with an immunotherapy drug, we see total rejection of the tumour. The nice thing is that some anti-TREM2 antibodies are already in clinical trials for another disease. We have to do more work in animal models to verify these results, but if those work, we’d be able to move into clinical trials fairly easily because there are already a number of antibodies available.”
T cells, a kind of immune cell, have the ability to detect and destroy tumour cells.
To survive, tumours create a suppressive immune environment in and around themselves that keeps T cells subdued.
A type of immunotherapy known as checkpoint inhibition wakes T cells from their quiescence so they can begin attacking the tumour.
But if the tumour environment is still immunosuppressive, checkpoint inhibition alone may not be enough to eliminate the tumour.
An expert on the immune system, Colonna has long studied a protein called TREM2 in the context of Alzheimer’s disease, where it is associated with underperforming immune cells in the brain.
Colonna and first author Martina Molgora, PhD, a postdoctoral researcher, realised that the same kind of immune cells, known as macrophages, also were found in tumours, where they produce TREM2 and promote an environment that suppresses the activity of T cells.
“When we looked at where TREM2 is found in the body, we found that it is expressed at high levels inside the tumour and not outside of the tumour,” Colonna said. “So it’s actually an ideal target, because if you engage TREM2, you’ll have little effect on peripheral tissue.”
Colonna and Molgora – along with colleagues Robert D. Schreiber, PhD, the Andrew M. and Jane M. Bursky Distinguished Professor; and William Vermi, MD, an immunologist at the University of Brescia – set out to determine whether inhibiting TREM2 could reduce immunosuppression and boost the tumour-killing powers of T cells.
As part of this study, the researchers injected cancerous cells into mice to induce the development of a sarcoma.
The mice were divided into four groups.
In one group, the mice received an antibody that blocked TREM2; in another group, a checkpoint inhibitor; in the third group, both; and the fourth group, placebo.
In the mice that received only placebo, the sarcomas grew steadily.
In the mice that received the TREM2 antibody or the checkpoint inhibitor alone, the tumours grew more slowly and plateaued or, in a few cases, disappeared.
But all of the mice that received both antibodies rejected the tumours completely.
The researchers repeated the experiment using a colorectal cancer cell line with similarly impressive results.
With the help of graduate student Ekaterina Esaulova, who works in the lab of Maxim Artyomov, PhD, an associate professor of pathology and immunology, the researchers analysed immune cells in the tumours of the mice treated with the TREM2 antibody alone.
They found that suppressive macrophages were largely missing and that T cells were plentiful and active, indicating that blocking TREM2 is an effective means of boosting anti-tumour T cell activity.
Further experiments revealed that macrophages with TREM2 are found in many kinds of cancers.
To assess the relationship between TREM2 expression and clinical outcomes, the researchers turned to The Cancer Genome Atlas, a publicly available database of cancer genetics jointly maintained by the National Cancer Institute and the National Human Genome Research Institute.
They found that higher levels of TREM2 correlated with shorter survival in both colorectal cancer and breast cancer.
The researchers are now expanding their study of TREM2 to other kinds of cancers to see whether TREM2 inhibition is a promising strategy for a range of cancers.
“We saw that TREM2 is expressed on over 200 cases of human cancers and different subtypes, but we have only tested models of the colon, sarcoma and breast, so there are other models to test,” Molgora said. “And then we also have a mouse model with a human version of TREM2.”
Added Colonna: “The next step is to do the animal model using the human antibody. And then if that works, we’d be ready, I think, to go into a clinical trial.”